Cited by 1,099Tuberous Sclerosis Complex ResearchVascular Malformations and HemangiomasPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Open access

McCormack, Francis X., Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G., Strange, Charlie, Nakata, Koh, Barker, Alan F., Chapman, Jeffrey T., Brantly, Mark L., Stocks, James M., Brown, Kevin K., Lynch, Joseph P., Goldberg, Hilary J., Young, Lisa R., Kinder, Brent W., Downey, Gregory P., Sullivan, Eugene J., Colby, Thomas V., McKay, Roy T., Cohen, Marsha M., Korbee, Leslie, Taveira-DaSilva, Angelo M., Lee, Hye-Seung, Krischer, Jeffrey P., Trapnell, Bruce C.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1100391PMC PMC3118601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). RESULTS: During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1100391

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,275
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250
Self-citation
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 648
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 525
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
The NHLBI Lymphangioleiomyomatosis Registry
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., MAURER, J. R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 466
Self-citation
Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E., Goncharov, D. A., Eszterhas, A., Hunter, D., Glassberg, M., Yeung, R. S., Walker, C., Noonan, D., Kwiatkowski, D., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 433
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 327
Lymphangioleiomyomatosis
McCormack, F. X. (2008) · CHEST Journal · doi:10.1378/chest.07-0898 · Cited by 303
Self-citation

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 1

Khanna D, 2010, Clin Exp Rheumatol, 28, S55

Sorted by citations

Items 701–800 of 999

Lymphangioleiomyomatosis Patient Research Priorities Survey (LAM-PREP)
Holz, M. K., Slattery, A. D., Pontz, E. J., Dreyer, S. R., Downey, G. P., Gupta, N., Sherman, S. E., Krymskaya, V. P., & Hoy, L. M. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100184 · Cited by 3
Self-citation
Current concepts in the pathogenesis and clinical management of lymphangioleiomyomatosis
O’Malley, D., Gupta, N., & McCarthy, C. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001185 · Cited by 3
Angiogenesis, Lymphangiogenesis and Lymphovascular Invasion: Prognostic Impact for Bladder Cancer Patients
Afonso, J., Lara, L. C., & Longatto‐Filho, A. (2012) · InTech eBooks · doi:10.5772/26676 · Cited by 3
Renal angiomyolipomatosis and Kaposi’s sarcoma: a possible link disrupted by sirolimus
Stallone, G., Infante, B., Tartaglia, L., Bruno, F., Gesualdo, L., & Grandaliano, G. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0833-6 · Cited by 3
Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis
Kinoshita, Y., Sakamoto, A., & Hidaka, K. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205701 · Cited by 3
Assessing the Population Impact of Published Intervention Studies
Coffinier, C., Teutsch, S. M., & Fielding, J. E. (2015) · NAM Perspectives · doi:10.31478/201506e · Cited by 3
Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis
Marsh, K. M., Schipper, D. A., Ferng, A. S., Johnson, K., Fisher, J. M., Knapp, S. M., Dicken, D. S., & Khalpey, Z. I. (2017) · Lung · doi:10.1007/s00408-017-0016-3 · Cited by 3
Chylous Ascites as a Presentation of Lymphangioleiomyomatosis
McLain, J. H., Khadarian, K. A., Shojaie, L., Lubman, R. L., Chang, C., Lindgren, B., & Shao, L. (2021) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000517 · Cited by 3
Leucyl-tRNA synthetase 1 is required for proliferation of TSC-null cells
Bae, J.-H., & Kim, J. H. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.080 · Cited by 3
Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function
Farré, X., Espín, R., Baiges, A., Blommaert, E., Kim, W., Giannikou, K., Herranz, C., Román, A., Sáez, B., Casanova, Á., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00375-2021 · Cited by 6
Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan
Egami, A., Takahashi, S., Kokubo, T., Boggarapu, S., & Beresford, E. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00914-2 · Cited by 3
Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition
Pietrobon, A., Yockell‐Lelièvre, J., Melong, N., Smith, L. J., Delaney, S. P., Azzam, N., Xue, C., Merwin, N. J., Lian, E. Y., Camacho‐Magallanes, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202302611 · Cited by 3
Lymphangioleiomyomatosis and mTOR inhibitors in real world—a narrative review
Park, S., & Lee, E. J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-778 · Cited by 3
Quantification of Proteus syndrome-associated lung disease
Ours, C., Buser, A., Hodges, M. B., Chen, M. Y., Sapp, J. C., Gochuico, B. R., & Biesecker, L. G. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-03013-9 · Cited by 3
A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC)
Nunes, B. A., Romano, A. K. F. G., Morgan, M. A. P., Gonçalves, A. A., Cardozo, L. F. M., Dufner‐Almeida, L. G., Haddad, L. A., Crippa, A. C. D. S., Antoniuk, S. A., & Abagge, K. T. (2024) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2023.11.004 · Cited by 3
Enhanced Gαq Signaling in TSC2 -Deficient Cells Is Required for Their Neoplastic Behavior
Trefier, A., Tousson-Abouelazm, N., Yamani, L., Ibrahim, S., Joung, K.-B., Pietrobon, A., Yockell‐Lelièvre, J., Hébert, T. E., Ladak, R. J., Takano, T., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0111oc · Cited by 3
Sirolimus Use During Pregnancy in Women with Lymphangioleiomyomatosis
Krishna, R., Johnson, S. R., Ataya, A., Baqir, M., Baldi, B. G., Girod, C. E., Diesler, R., Henske, E. P., Xu, K., & Gupta, N. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202504-433rl · Cited by 3
Esclerosis tuberosa de Bourneville
Georgescou, G., de la Vaissière, S., Castelnau, P., Halimi, J.-M., & Toutain, A. (2015) · EMC - Dermatología · doi:10.1016/s1761-2896(15)72848-7 · Cited by 3
Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis.
Aghaeimeybodi, F., Najafizadeh, K., Razavi-Ratki, S. K., & Namiranian, N. (2019) · Europe PMC (PubMed Central) · doi:10.22088/cjim.10.1.7 · Cited by 3
A Case of Lymphangioleiomyomatosis (LAM) of the Lung in a Patient with a History of Breast Cancer
Koç-Günel, S., Tekeli, N., Smaczny, C., Vogl, T. J., & Rohde, G. G. U. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.914355 · Cited by 3
Refractory chylous effusions in lymphangioleiomyomatosis patient post lung transplant
Jacob, S., Ali, M., Ahmed, M. M. E., Itkin, M. G., Narula, T., Pham, S. M., & Erasmus, D. B. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20921332 · Cited by 3
Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors
Inoue, C., Miki, Y., Saito, R., Kobayashi, K., Seyama, K., Okada, Y., & Sasano, H. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153758 · Cited by 3
Interstitial lung diseases: an overview
Karampitsakos, Τ., Wijsenbeek, M. S., Herazo‐Maya, J. D., Τzouvelekis, Α., & Kreuter, M. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10017322 · Cited by 3
Extrapulmonary lymphangioleiomyomatosis mimicking lymphoma metastatic to uterus
Vatansever, D., Sözen, H., İyibozkurt, A. C., Comba, C., Yavuz, E., & Topuz, S. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12628 · Cited by 3
Surgical treatment of chylothorax caused by lymphangioleiomyomatosis.
Liu, M., Wu, B., Cui, Y., Chang, D., Zhang, S., & Gong, M. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.01.15 · Cited by 3
Tuberous Sclerosis Complex 2 Loss of Heterozygosity in Patients with Lung Disease and Cancer
Zhang, L., Pacheco–Rodriguez, G., Steagall, W. K., Kato, J., Haughey, M., Fontana, J. R., Manganiello, V. C., & Moss, J. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1480le · Cited by 3
Self-citation
Trasplante pulmonar en la linfangioleiomiomatosis esporádica. Estudio de 7 casos
Barrera, E. A., Franch, N. M., Cuesta, J. C. P., Vera-Sempere, F. J., & Alarcón, J. P. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.036 · Cited by 3
The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps
Harari, S. A., Cassandro, R., & Torre, O. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0272le · Cited by 3
Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases
Nishino, K., Yoshimi, K., Shibuya, T., Hayashi, T., Mitani, K., Kobayashi, E., Ichikawa, M., Asao, T., Suzuki, Y., Sato, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7769 · Cited by 3
Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator‐initiated prospective study
Kitamura, N., Seyama, K., Inoue, Y., Nagai, K., Suzuki, M., Moriyama, H., Takada, T., Tazawa, R., Hirai, T., Mishima, M., et al. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4259 · Cited by 3
Self-citation
Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus
Sakaue, T., Tominaga, M., Niizeki, T., Zaizen, Y., Matsukuma, K., Koganemaru, M., Hoshino, T., & Torimura, T. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.01.002 · Cited by 3
Pulmonary lymphangioleimyomatosis and systemic lupus erythematosus in a menopausal woman
Hong, H., Yang, R., Li, X., Wang, M., & Ma, Z. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0889-2 · Cited by 3
Diffuse cystic lung disease
Averyanov, A., Коган, Е. А., Lesnyak, V., Васильевна, Д. О., & Stepanyan, I. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815375-8.00009-1 · Cited by 3
Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus
Ko, Y., Asakawa, K., Tobino, K., Oguma, T., Hirai, T., Takada, T., Takahashi, K., & Seyama, K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03345 · Cited by 3
Successful management of sirolimus toxicity in a hematopoietic stem cell transplant patient using automated red blood cell exchange
Nizzi, F., Rees, M., Salzberg, D. B., & Ngwube, A. I. (2020) · Transfusion · doi:10.1111/trf.16064 · Cited by 3
Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
Sayah, D. M., & Pilewski, J. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.002 · Cited by 3
Metabolic signatures of lymphangioleiomyomatosis in biofluids: nuclear magnetic resonance (NMR)-based metabonomics of blood plasma: a case-control study
Gu, W., Pan, Y., Zhao, W., Liu, J., & Meng, Y. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6420 · Cited by 3
Tuberous Sclerosis (Bourneville Disease)
Islam, M. P., Panteliadis, C. P., & Curatolo, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-87893-1_27 · Cited by 3
LYMPHANGIOLEIOMYOMATOSIS
Ilkovich, M. M., Novikova, L., & Baranova, O. P. (2024) · doi:10.18093/978-5-6048754-6-9-2024-2-364-379 · Cited by 3
O caminho à frente da linfangioleiomiomatose: um ensaio para cada paciente, cada paciente em um ensaio
McCormack, F. X. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000400002 · Cited by 3
Self-citation
Imaging Biomarkers in Lymphangioleiomyomatosis Clinical Trials. A Wolf in Sheep’s Clothing?
Washko, G. R., & Párraga, G. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201512-818ed · Cited by 3
The discovery of novel mechanisms for lymphangioleiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders
Kristof, A. S., & Ortega, V. E. (2019) · European Respiratory Journal · doi:10.1183/13993003.00863-2019 · Cited by 3
Needle in the Haystack: Finding the Elusive Lymphangioleiomyomatosis Cell
Steagall, W. K., & Moss, J. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2436ed · Cited by 3
Self-citation
STAT1 Promotes PD-L1 Activation and Tumor Growth in LymphangioleiomyomatosisPreprint
Olatoke, T., Zhang, E. Y., Wagner, A. F., He, Q., Li, S., Astrinidis, A., McCormack, F. X., Xu, Y. J., & Yu, J. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.11.627871 · Cited by 3
Self-citation
Impact of Rapamycin on Longevity: Updated Insights
Sanati, M., Afshari, A. R., Aminyavari, S., Banach, M., & Sahebkar, A. (2024) · Archives of Medical Science · doi:10.5114/aoms/191565 · Cited by 3
Characteristics and outcomes of patients with LAM receiving sirolimus in France based on real-life data
Cottin, V., Cases, A., Bourdin, V., Reynaud‐Gaubert, M., Hirschi, S., Kerjouan, M., Diesler, R., Chardès, B., Fievez, S., Assi, N., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1494713 · Cited by 2
Lymphangioleiomyomatosis, sporadic and associated with tuberous sclerosis: a pulmonologist’s point of view
Makarova, M. A., & Belevskiy, А. S. (2025) · PULMONOLOGIYA · doi:10.18093/0869-0189-2025-35-3-403-411 · Cited by 2
Sporadic Lymphangioleiomyomatosis in a 35-Year-Old Female Patient: A Rare Cause of Spontaneous Pneumothorax
Rodenko, P. N., Elefteratos, J., Rodenko, E. L., Herrell, C., & Townsend, T. (2025) · Cureus · doi:10.7759/cureus.87346 · Cited by 2
Extracellular Matrix and Fibroblast Activation in Lymphangioleiomyomatosis
Mukhitov, A. R., Evans, J. F., Han, T., Ledwell, O. A., Rue, R. W., Obraztsova, K., Lin, S. M., Basil, M. C., Cantu, E., Tang, Y., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2025-0237oc · Cited by 2
Current Perspectives on The Diagnosis and Management of Lymphangioleiomyomatosis
Saluja, P., & Gupta, N. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.002 · Cited by 2
Canagliflozin as a Potential Preclinical Therapy for Tuberous Sclerosis Complex: Inhibition of Tsc2−/− Cell Proliferation via Cell Cycle Arrest and Mitochondrial Dysfunction
Ye, J., Liu, B., Wu, J., Gao, H., Wei, Q., Su, K., Zheng, K., Dai, X., Xu, T., Wang, Y., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525749 · Cited by 3
Natural senotherapeutics in respiratory health: Addressing cellular senescence, inflammaging, and immunosenescence in the aging lung
Juan, M. E., Verdaguer, E., Prohens, R., Ettcheto, M., Auladell, C., Camins, A., & Olloquequi, J. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178620 · Cited by 2
Pulmonary research in 2013 and beyond: a National Heart, Lung, and Blood Institute perspective
Kiley, J. P., & Senior, R. M. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00305.2012 · Cited by 2
The Importance of Genetic Factors in the Management of Spontaneous Pneumothorax
Matsumoto, K., & Marciniak, S. J. (2020) · Current Pulmonology Reports · doi:10.1007/s13665-020-00248-w · Cited by 2
A pulmonary lymphangioleiomyomatosis with multi-site angiomyolipoma: a case report
He, F., Zhong, J., Chai, R., Sheng, J., Zhao, T., & Han, Y. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2539 · Cited by 2
Cardiac self-limiting rhabdomyomas in a neonatal patient with tuberous sclerosis complex: a case report with negative genetic testing
Zhou, H., Zheng, Z., Tu, Z., Li, Y., Yang, J., & Fan, C. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1263631 · Cited by 2
Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study
Sakurai, T., Kanou, T., Funaki, S., Fukui, E., Kimura, T., Ose, N., Inoue, Y., & Shintani, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.05.008 · Cited by 2
Self-citation
Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study
Wang, W., Zhou, J., Kong, X., Wang, Y., Wu, Q., Gong, X., Tai, J., Pan, Y., Huang, H., Zhao, Z., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03260-4 · Cited by 2
Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis
Baldi, B. G., Feitosa, P. H. R., Rubin, A. S., Amaral, A. F., Freitas4, C. S. G., da Costa, C. H., Mancuzo, E. V., do Nascimento, É. C. T., Araújo, M. S., Rocha, M. J. J., et al. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240378 · Cited by 2
mTOR blockade mitigates chemotherapy drug-induced intestinal toxicity via inhibition of pyroptosis
Wang, X., Gao, F., Guan, J., Zhang, L., Du, L., Zhao, Y., Gao, F., Zhao, K., He, W., & Lin, J. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167913 · Cited by 2
Two cases of pulmonary lymphangioleiomyomatosis in postmenopausal women
Ishii, H., Kushima, H., Watanabe, K., & Kadota, J. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.02.002 · Cited by 2
Diffuse Lung Cysts in a Man with Polycystic Kidney Disease
Brown, S.-A. W., Jacobi, A., Mathur, A., & Dua, S. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201610-765cc · Cited by 2
Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC‐AML patients with treatment of mTOR inhibitors
Wang, W., Wang, Z., Zhao, Y., Wang, X., Li, H., & Zhang, Y. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13631 · Cited by 2
Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipomas
Vaughan, R. M., Kordich, J. J., Chan, C.-Y., Sasi, N. K., Celano, S. L., Sisson, K. A., Baren, M. V., Kortus, M. G., Aguiar, D. J., Martin, K. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852859 · Cited by 3
Lymphangioleiomyomatosis
Bourke, S. J. (2020) · doi:10.1093/med/9780198746690.003.0426 · Cited by 2
A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs
Prosdocimi, M., Zuccato, C., Cosenza, L. C., Borgatti, M., Lampronti, I., Finotti, A., & Gambari, R. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17845.2 · Cited by 2
Pulmonary Hypertension in Orphan Lung Diseases
Montani, D., Thoré, P., Jutant, E., & Humbert, M. J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_41 · Cited by 2
Diffuse cystic lung diseases including lymphangioleiomyomatosis
Elia, D., Caminati, A., Tescaro, L., Cassandro, R., & Harari, S. A. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10017622 · Cited by 2
Current and advancing systemic treatment options for soft tissue sarcomas
Harris, S. J., Benson, C., & Jones, R. L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1074176 · Cited by 2
Is There Still a Role for Hormonal Blockade in Lymphangioleiomyomatosis?
Baldi, B. G., & de Carvalho, C. R. R. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0315le · Cited by 2
Getting to the finish line with mTORC1-targeted therapy
Henske, E. P. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64227 · Cited by 2
Radical reduction of smooth muscle cells in explanted lung of a LAM patient treated with sirolimus: First case report
Montero, Á., Román, A., & Berastegui, C. (2012) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.12.004 · Cited by 2
The importance of biobank and nationwide registry for lymphangioleiomyomatosis in a small sized country
Struik, M. H. L., van Moorsel, C. H. M., van Beek, F. T., Veltkamp, M., McCormack, F. X., & Grutters, J. C. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1022529 · Cited by 2
Self-citation
A 29-Year-Old Woman With an Intractable Postoperative Pleural Effusion and Pulmonary Parenchymal Opacification
Min, H. K., Jung, J. I., Song, J. S., Park, C. K., Kim, Y. K., & Kang, J. Y. (2012) · CHEST Journal · doi:10.1378/chest.11-1913 · Cited by 2
Distinguishing Between Lymphangioleiomyomatosis and Carcinomatous Peritonitis in a Patient With Ovarian Cancer
Hirasawa, A., Sato, T., Ueno, M., Akahane, T., Susumu, N., Betsuyaku, T., & Aoki, D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3019 · Cited by 2
LAM: Neue Therapien – neue Chancen?
Wirtz, H. R. W. (2015) · Der Pneumologe · doi:10.1007/s10405-015-0020-3 · Cited by 2
Clinical Impact of mTOR Inhibitors on the Management of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex
Krueger, D. A. (2011) · International Journal of Clinical Reviews · doi:10.5275/ijcr.2011.08.10 · Cited by 2
LAM/TSC Cell Migration to Uterus in an Experimental Model of Lymphangioleiomyomatosis. Regulation by Anti-Epidermal Growth Factor Receptor Antibody and Rapamycin
Ancona, E. C. S. (2014) · Journal of Cytology & Histology · doi:10.4172/2157-7099.s4-007 · Cited by 2
Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus
Cabeza, L. R., Ruiz-Cobos, M. Á., & Casanova, Á. (2016) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2016.04.002 · Cited by 2
Durability of Sirolimus for Lymphangioleiomyomatosis
Martirossian, A. N., Shah, S. K., Carrete, L., Valle, J., & Valentine, V. G. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.11.028 · Cited by 2
EFFECTS OF AQUEOUS MEDIUM, TWEEN-20 AND FLOW ON THE STABILITY OF SIROLIMUS
ZHENG, Q., Chu, Z., LI, X., Kang, H., YANG, X., & Fan, Y. (2017) · Journal of Mechanics in Medicine and Biology · doi:10.1142/s0219519417500397 · Cited by 2
A Novel Mutation in TSC2 Gene: A 34-Year-Old Female with Pulmonary Lymphangioleiomyomatosis with Concomitant Hepatic Lesions
Nadiri, M., Raeisi, M., & Mousavi‐Aghdas, S. A. (2018) · Case Reports in Pulmonology · doi:10.1155/2018/5928231 · Cited by 2
Have Noninvasive Imaging Studies Supplanted the Need for Invasive Hemodynamics: Lessons Learned from Lymphangioleiomyomatosis.
Strom, J. (2018) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2018.06.003 · Cited by 1
COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis
Kato, M., Kanehiro, Y., Yoshimi, K., Kodama, Y., Sekiya, M., Sato, T., Takahashi, K., & Seyama, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.07.004 · Cited by 2
Vitamin D binding protein: a new biomarker of disease severity in lymphangioleiomyomatosis
Liu, H.-J., & Henske, E. P. (2018) · European Respiratory Journal · doi:10.1183/13993003.01886-2018 · Cited by 2
Chest Imaging for Precision Medicine
Ash, S. Y., Estépar, R. S. J., & Washko, G. R. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_8 · Cited by 2
Genetic Interstitial Lung Disease
Garcia, C. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00001-x · Cited by 3
Sirolimus for the Treatment of Vascular Anomalies
Mack, J. M., Adams, D. M., & Ricci, K. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-25624-1_4 · Cited by 2
Raising the Flag for Mast Cells as a Novel Target in Lymphangioleiomyomatosis
Goldklang, M. P. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202104-0872ed · Cited by 2
Spindle cell lesion on fine needle aspiration as an initial step for diagnosis of lymphangioleiomyomatosis: Report of a rare case
Manukyan, I., Sidawy, M. K., & DeBrito, P. (2021) · Diagnostic Cytopathology · doi:10.1002/dc.24802 · Cited by 2
TSC1 and TSC2: Tuberous Sclerosis Complex and Its Related Epilepsy Phenotype
Napoli, C. D., Gennaro, A., Lupica, C., Falsaperla, R., Leonardi, R., Garozzo, M. T., Polizzi, A., Praticò, A. D., Zanghì, A., & Ruggieri, M. (2021) · Journal of Pediatric Neurology · doi:10.1055/s-0041-1727142 · Cited by 2
Pulmonary Hypertension in Orphan Lung Diseases
Montani, D., Girerd, B., Seferian, A., Godinas, L., & Humbert, M. J. C. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_33 · Cited by 2
Sporadic lymphangioleiomyomatosis
Chen, W.-C., Shen, T., & Tu, C.-Y. (2014) · QJM · doi:10.1093/qjmed/hcu019 · Cited by 2
Lymphangioleiomyomatosis
Berg, J. Z., & Young, L. R. (2015) · Respiratory medicine · doi:10.1007/978-3-319-23998-9_8 · Cited by 2
Self-citation
Lymphangioleiomyomatose
Wirtz, H. R. W., Kirsten, D. K., & Watz, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_17 · Cited by 2
Tuberous sclerosis: its neurological and neuropsychiatric aspects and a case report
Varghese, J. J., Thomas, S. P., & Kallivayalil, R. A. (2019) · Kerala Journal of Psychiatry · doi:10.30834/kjp.31.1.2019.150 · Cited by 2
Cystic Lung Diseases Causing Spontaneous Pneumothorax
Zhang, C. (2022) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2022.00011 · Cited by 2
Renal Involvement in Tuberous Sclerosis Complex
Bissler, J. J., & Batchelor, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_118 · Cited by 2
Exosome Release by Glucose Deprivation Is Important for the Viability of TSC-Null Cells
Bae, J.-H., & Kim, J. H. (2022) · Cells · doi:10.3390/cells11182862 · Cited by 2
Lung Tumors
Popper, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-55743-0_17 · Cited by 2

Authors: McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H.-S., Krischer, J. P., & Trapnell, B. C.
Affiliations: University of Cincinnati (US)
National Hospital Organization (JP)
National Institutes of Health (US)
University of Toronto (CA)
Medical University of South Carolina (US)
Niigata University Medical and Dental Hospital (JP)
Oregon Health & Science University (US)
Cleveland Clinic (US)
University of Florida (US)
The University of Texas Health Science Center at Tyler (US)
National Jewish Health (US)
Cincinnati Children's Hospital Medical Center (US)
Harvard University (US)
United Therapeutics (United States) (US)
Mayo Clinic (US)
University of South Florida (US)
ORCID: McCormack, Francis X.
Inoue, Yoshikazu
Moss, Joel
Singer, Lianne G.
Strange, Charlie
Nakata, Koh
Brantly, Mark L.
Brown, Kevin K.
Goldberg, Hilary J.
Young, Lisa R.
Downey, Gregory P.
Colby, Thomas V.
Lee, Hye-Seung
Krischer, Jeffrey P.
Trapnell, Bruce C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-04-28
Volume: 364
Issue: 17
Pages: 1595-1606
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1100391
PMC: PMC3118601
OpenAlex: W2147028601
Semantic Scholar: 0af4a52c455e626ae3c70aa2ba2d64208b19a305
Cited by: 1,099
References: 27
Citations by year: 2026: 38 · 2025: 54 · 2024: 77 · 2023: 70 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 78 · 2018: 77 · 2017: 65 · 2016: 78 · 2015: 87 · 2014: 71 · 2013: 81 · 2012: 68
FWCI: 54.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Tuberous Sclerosis Alliance
Pfizer
LAM Foundation
Cincinnati Children's Hospital Medical Center
National Institutes of Health (1ul1rr026314-01, 1UL1RR026314)
U.S. Food and Drug Administration (FD003362, R01 FD003362)
Canadian Institutes of Health Research
National Heart, Lung, and Blood Institute (R01HL085453, ZIAHL002541)
National Center for Research Resources (1UL1 RR-026314-01, U54RR019259, UL1-RR026314, U54RR019498, RR019498, RR019259)
NHLBI Division of Intramural Research
Topics: Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
Health Sciences › Medicine › Surgery › Vascular Malformations and Hemangiomas
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: lymphangioleiomyomatosis, rapamycin, mTOR signaling, lung function, FEV1, VEGF-D, quality of life, adverse events, drug discontinuation, cystic lung disease
MeSH terms: Adult, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Middle Aged, Quality of Life, Vital Capacity, Lymphangioleiomyomatosis, Observation, Sirolimus, Medication Adherence, Intention to Treat Analysis, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks